Reviewer’s report

Title: Nature and Prevalence of Adverse drug reaction of Antiretroviral Medications in Halibet National Referral Hospital: a retrospective study.

Version: 0 Date: 16 Nov 2018

Reviewer: Kheirollah Gholami

Reviewer's report:

Dear editor,

In this manuscript the authors have studied the prevalence, nature, seriousness and possible risk factor of antiretroviral therapy (ART) associated with adverse drug reactions (ADRs). By screening the 309 patients, they have reported that ADRs associated with ART drugs are highly prevalent and also the major risk factor is the CD4 count below 200.

1) The authors have mentioned that patients aged 60 years and above were excluded from the study because they may have comorbidities. But one should noted that patients with age below 60 can also have comorbidities.
2) It is unclear which statistical tests are used.
3) It was better to mention in the results section that when the first ADR was happened.
4) The authors said that 70 patients have comorbidities but they did not reported which diseases coexisted. For example, which percent of patients had hepatitis B or C simultaneously?
5) In the method section it is mentioned that the study was a three month retrospective study. But in the results section the authors have said the occurrence of ADR such as Lipodystrophy is delayed and appears 2-3 years after ART onset. So, it seems that the patient groups were not homogeneous and the authors should explain this point clearly.
6) There is some typos. For example protein inhibitor, Zidoudine.

According to the above criticisms, at the moment, I can not recommend this paper to be published in the high quality journal "BMC Pharmacology and Toxicology". My suggestion is major revision.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal